REGENXBIO (RGNX) stock: insider trades, news & valuation
Health Care · Net buyingShare price and insider trades
REGENXBIO insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $950K and 2 sold $1.2M of RGNX stock on the open market.
Get emailed when insiders cluster-buy stocks like RGNX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
RGNX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $950K | 2 | $502K | 2 |
| Q2 2026 | — | 0 | $385K | 2 |
| Q1 2026 | — | 0 | $53K | 1 |
| Q4 2025 | — | 0 | $263K | 1 |
| Q3 2025 | — | 0 | $76K | 1 |
Valuation, profit and volume
Pick score 43/100Summary
Over the past 12 months, 1 REGENXBIO Inc. insider reported open-market purchases totaling $950K, while 2 insiders reported sales totaling $1.2M. 7 of 7 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
RGNX stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 27SEC | Gregory Austin CiongoliDirector | Buy | 53,407118,035 held (+83%) | $9.36 | $500K | -13.8% | — |
| Aug 27SEC | Gregory Austin CiongoliDirector | Buy | 49,19664,628 held (+319%) | $9.14 | $450K | -11.7% | — |
| Jul 6SEC | Steve PakolaChief Medical Officer | Sell Plan | 2,161213,009 held (−1%) | $13.64 | $29K | -40.8% | — |
| Jul 1SEC | Steve PakolaChief Medical Officer | Sell Plan | 36,725213,009 held (−15%) | $12.86 | $472K | -37.2% | — |
| Jul 1SEC | Steve PakolaChief Medical Officer | Sell Plan | 19,608213,009 held (−8%) | $11.04 | $216K | -26.9% | — |
| May 13SEC | Steve PakolaChief Medical Officer | Sell Plan | 15,309232,617 held (−6%) | $11.02 | $169K | -26.8% | — |
| Mar 12SEC | Steve PakolaChief Medical Officer | Sell Plan | 5,124247,926 held (−2%) | $10.35 | $53K | -22.0% | — |
| Oct 10SEC | Curran SimpsonCEO | Sell Plan | 20,811216,162 held (−9%) | $12.62 | $263K | -36.1% | — |
| Oct 1SEC | Curran SimpsonCEO | Sell Plan | 7,624236,973 held (−3%) | $10.03 | $76K | -19.5% | — |
Insiders at REGENXBIO Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Gregory Austin CiongoliDirector | $950K | — | Aug 27, 2026 | — |
| Steve PakolaChief Medical Officer | — | $940K | Jul 6, 2026 | — |
| Curran SimpsonCEO | — | $339K | Oct 10, 2025 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
RGNX stock: common questions
Are REGENXBIO Inc. insiders buying RGNX stock?
In the past 12 months, 1 insiders reported open-market purchases of RGNX worth $950K. The latest was Director Gregory Austin Ciongoli bought $500K of RGNX at $9.36 — largest purchase by this insider in our records; raises the stake by 83%.
Are REGENXBIO Inc. insiders selling RGNX stock?
2 insiders reported sales worth $1.2M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is RGNX's 52-week range?
Over the past year RGNX has traded between $5.65 and $15.98. It last closed at $8.07 on Oct 9, 2026.